Market Overview:
The global coagulation factor XI market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The market growth can be attributed to factors such as rising prevalence of thrombosis, bleeding and clotting disorders, increasing incidence of acute ischemic stroke, and growing demand for coagulation factor XI products. However, the high cost of treatment and lack of awareness about these products are some factors that may restrain the growth of this market during the forecast period. The global coagulation factor XI market can be segmented on the basis of type into MR-1007, IONIS-FXIRx, EP-7041, AB-022 BMS-262084 Others). The MR - 1007 segment is expected to account for a major share in terms revenue in 2018 owing to its high efficacy and safety profile. On the basis application ,the thrombosis segment accounted for majority share in 2017 due increased prevalence rate across globe .However ,bleeding disordersegmentis projectedto register highest CAGR over forecast period owingto increase incidencesof hemophilia& von Willebrand disease patients .
Product Definition:
MR-1007:
MR-1007 (also known as Coagulation Factor XI) is a single-chain plasma protein, which facilitates the binding of blood coagulation factors. It has been studied in detail for its ability to promote hemostasis and prevent bleeding disorders. MR-1007 is also used in wound healing applications due to its ability to inhibit angiogenesis and reduce inflammation along with promoting tissue regeneration.
IONIS-FXIRx:
IONIS-FXIRx is a novel, non-invasive technology that uses near infrared light to measure the levels of coagulation factors in the blood. The test helps detect and monitor diseases such as hemophilia A and B, Christmas disease (XVI), chronic idiopathic hypoproteinemia (CIH) and other rare disorders involving abnormal levels of coagulation factors.
Application Insights:
Acute ischemic stroke accounted for the largest share of 23.3% in the global coagulation factor XI market in 2017 owing to its high incidence and mortality rates. According to a study, around 5-10% of patients suffering from acute ischemic stroke require anticoagulant therapy; however, only about 25-30% of these patients are administered with warfarin due to various factors such as patient age, underlying medical conditions (such as atrial fibrillation), and other drugs being taken by the patient.
The others segment includes deep vein thrombosis (DVT) prophylaxis, pulmonary embolism prophylaxis, dental procedures related bleeding disorders such as hemophilia and easy bruising.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable reimbursement policies, and increasing healthcare expenditure are some factors responsible for its growth. In addition, growing interest among patients in cost-saving alternatives to conventional therapies is expected to drive the demand for factor XI products over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to rising disposable income and improving healthcare infrastructure coupled with an increase in awareness regarding clotting disorders treatment options especially for expensive drugs such as factor XIIs that have a high price per dose. Moreover, increasing prevalence of cardiovascular diseases & hypertension which result from unhealthy lifestyles will further boost product demand over the coming years (8% annually).
Growth Factors:
- Increasing incidence of bleeding disorders and hemophilia
- Rising demand for blood transfusion and plasma-based therapies
- Growing number of surgical procedures requiring blood clotting factors
- Technological advancements in coagulation factor XI products
- increasing prevalence of lifestyle diseases
Scope Of The Report
Report Attributes
Report Details
Report Title
Coagulation Factor XI Market Research Report
By Type
MR-1007, IONIS-FXIRx, EP-7041, AB-022, BMS-262084, Others
By Application
Thrombosis, Bleeding and Clotting Disorders, Acute Ischemic Stroke, Others
By Companies
Bayer AG, Bristol-Myers Squibb Company, Cambryn Biologics LLC, eXithera Pharmaceuticals, Inc, Ionis Pharmaceuticals, Inc., LegoChem Biosciences, Inc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
174
Number of Tables & Figures
122
Customization Available
Yes, the report can be customized as per your need.
Global Coagulation Factor XI Market Report Segments:
The global Coagulation Factor XI market is segmented on the basis of:
Types
MR-1007, IONIS-FXIRx, EP-7041, AB-022, BMS-262084, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Thrombosis, Bleeding and Clotting Disorders, Acute Ischemic Stroke, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bayer AG
- Bristol-Myers Squibb Company
- Cambryn Biologics LLC
- eXithera Pharmaceuticals, Inc
- Ionis Pharmaceuticals, Inc.
- LegoChem Biosciences, Inc
Highlights of The Coagulation Factor XI Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- MR-1007
- IONIS-FXIRx
- EP-7041
- AB-022
- BMS-262084
- Others
- By Application:
- Thrombosis
- Bleeding and Clotting Disorders
- Acute Ischemic Stroke
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Coagulation Factor XI Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Coagulation Factor XI is a protein that helps to form blood clots. It is also known as coagulation factor XIa.
Some of the key players operating in the coagulation factor xi market are Bayer AG, Bristol-Myers Squibb Company, Cambryn Biologics LLC, eXithera Pharmaceuticals, Inc, Ionis Pharmaceuticals, Inc., LegoChem Biosciences, Inc.
The coagulation factor xi market is expected to register a CAGR of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Coagulation Factor XI Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Coagulation Factor XI Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Coagulation Factor XI Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Coagulation Factor XI Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Coagulation Factor XI Market Size & Forecast, 2020-2028
4.5.1 Coagulation Factor XI Market Size and Y-o-Y Growth
4.5.2 Coagulation Factor XI Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 MR-1007
5.2.2 IONIS-FXIRx
5.2.3 EP-7041
5.2.4 AB-022
5.2.5 BMS-262084
5.2.6 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Thrombosis
6.2.2 Bleeding and Clotting Disorders
6.2.3 Acute Ischemic Stroke
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Coagulation Factor XI Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Coagulation Factor XI Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 MR-1007
9.6.2 IONIS-FXIRx
9.6.3 EP-7041
9.6.4 AB-022
9.6.5 BMS-262084
9.6.6 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Thrombosis
9.10.2 Bleeding and Clotting Disorders
9.10.3 Acute Ischemic Stroke
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 MR-1007
10.6.2 IONIS-FXIRx
10.6.3 EP-7041
10.6.4 AB-022
10.6.5 BMS-262084
10.6.6 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Thrombosis
10.10.2 Bleeding and Clotting Disorders
10.10.3 Acute Ischemic Stroke
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 MR-1007
11.6.2 IONIS-FXIRx
11.6.3 EP-7041
11.6.4 AB-022
11.6.5 BMS-262084
11.6.6 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Thrombosis
11.10.2 Bleeding and Clotting Disorders
11.10.3 Acute Ischemic Stroke
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 MR-1007
12.6.2 IONIS-FXIRx
12.6.3 EP-7041
12.6.4 AB-022
12.6.5 BMS-262084
12.6.6 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Thrombosis
12.10.2 Bleeding and Clotting Disorders
12.10.3 Acute Ischemic Stroke
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 MR-1007
13.6.2 IONIS-FXIRx
13.6.3 EP-7041
13.6.4 AB-022
13.6.5 BMS-262084
13.6.6 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Thrombosis
13.10.2 Bleeding and Clotting Disorders
13.10.3 Acute Ischemic Stroke
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Coagulation Factor XI Market: Competitive Dashboard
14.2 Global Coagulation Factor XI Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Bayer AG
14.3.2 Bristol-Myers Squibb Company
14.3.3 Cambryn Biologics LLC
14.3.4 eXithera Pharmaceuticals, Inc
14.3.5 Ionis Pharmaceuticals, Inc.
14.3.6 LegoChem Biosciences, Inc
